Prof. Pierantonio Menna

Prof. Pierantonio Menna is an Italian clinical pharmacologist. He graduated in Pharmaceutical Chemistry and Technology in 1999 from the University of Chieti-Pescara, where he received his PhD in Aging Sciences. He subsequently completed a postdoctoral training period at the Center of Excellence in Aging Research (CESI) at the University of Chieti and, between 2004 and 2005, he held a Research Fellowship at the Cancer Pharmacology Center – Mass Spectrometry Unit of the University of Pennsylvania School of Medicine in Philadelphia. In 2015, he specialized in Medical Pharmacology at the University of Rome “La Sapienza”. In 2007, he joined theUniversità Campus Bio-Medico di RomaHe was a pharmacologist member of the Ethics Committee of the Campus Bio-Medico University in the period 2019-2022. Since June 2021 he has held the role of Associate Professor of Pharmacology at the Departmental Faculty of Sciences and Bio-Technologies of theUniversità Campus Bio-Medico di RomaIn 2025, he obtained the National Scientific Qualification for the role of Full Professor in the 05/G1 Competitive Sector - Pharmacology, Clinical Pharmacology, and Pharmacognosy. He is currently Deputy Director of the School of Specialization in Pharmacology and Clinical Toxicology at the same university. His research and clinical activity focuses primarily on pharmacokinetics, pharmacodynamics, and pharmacogenetics, with a strong focus on precision medicine. He is the author of over seventy scientific publications indexed in PubMed, as well as numerous book chapters and presentations at national and international conferences.

PRE-UNIVERSITY AND UNIVERSITY EDUCATION

- Diploma in Industrial Chemistry (July 1994)

- Master's Degree in Pharmaceutical Chemistry and Technology, University “G. d'Annunzio”, Chieti-Pescara (1994-1999)

- Qualification to practice the profession (2000)

POST-GRADUATE EDUCATION

- Specialization in Medical Pharmacology, La Sapienza University of Rome (2010-2015)

- Certified course "Application aspects of the Rules of Good Clinical Practice (GCP)" (2010)

- Certified course "Data Management (DM)" (2010)

- Certified course "Application aspects of the Rules of Good Clinical Laboratory Practice (GCLP)" (2010)

- PhD in “Science of Aging”, University “G. d'Annunzio of Chieti (2001-2005)

POST-GRADUATE PROFESSIONAL EXPERIENCE IN ITALY

- Research Collaboration Grant, Faculty of Medicine and Surgery, Università Campus Bio-Medico di Roma (2008-2010)

- Research Collaboration Grant, Faculty of Medicine and Surgery, University “G. d'Annunzio” Chieti-Pescara (2003-2008)

- Research Collaboration Grant, Faculty of Pharmacy, Department of Pharmaceutical Sciences, University “G. d'Annunzio” Chieti-Pescara (2001-2002)

- Collaborations in research in the regime of occasional professional service at the Pharmacology laboratory, University "G.d'Annunzio" of Chieti-

Pescara (2000-2001)

POST-GRADUATE PROFESSIONAL EXPERIENCE ABROAD

- Visiting Scientist, University of Pennsylvania, Department of Pharmacology and Cancer Center, Philadelphia, PA. (September 2004 - September 2005)

ACADEMIC CAREER

- Achievement of National Scientific Qualification for the role of Full Professor in the Competitive Sector 05/G1 - Pharmacology, Clinical Pharmacology and Pharmacognosy. (2025)

- Associate Professor in Pharmacology, Departmental Faculty of Sciences and Technologies for Man and the Environment, Università Campus Bio-Medico di Roma. (2021)

ASSISTANCE ACTIVITY

- Since 2009 Responsible for the Management of the Quality System of the Pharmaco-Toxicology Laboratory - Clinical Pharmacology Unit - General Hospital

Campus Bio-Medico University of Rome

- Since 2009, Head of the "Pharmaco-Toxicology Laboratory for Healthcare", Clinical Pharmacology Unit - Fondazione Policlinico Universitario Campus Bio-Medico di Roma

OTHER ACTIVITIES'

- 2022-present. Scientific Coordinator of the Level II University Master's Degree in "Clinical Research, Open Innovation, and Market Access in the Digital Age." Università Campus Bio-Medico di Roma.

- 2019-2022. Pharmacologist Member of the Ethics Committee for Clinical Trials, Università Campus Bio-Medico di Roma.

- 2018-present. Member of the "Antimicrobial Stewardship" Working Group, Fondazione Policlinico Universitario Campus Bio-Medico in Rome.

RESEARCH LINES

- Cardiac metabolism of anticancer anthracyclines and cardiotoxicity: Structure-activity studies in translational models of human myocardium.

- Development of preclinical models for the screening and study of the structure-activity relationships of the cardiotoxicity of new anticancer drugs.

- Metabolism of anticancer anthracyclines by hypervalent hemoproteins: dosage of metabolites. Cardiac and systemic pharmacokinetics of anthracyclines

anticancer.

- Pharmacokinetics of antifungals in hematological patients.

- Pharmacokinetics of tyrosine kinase inhibitors in patients in hematological patients.

- Research, development and validation of analytical methods applied to Therapeutic Drug Monitoring in mass spectrometry.

- Preclinical and clinical cardiovascular safety profile of tyrosine kinase inhibitors with antileukemic activity.

- Quality systems in Phase I studies

- Management and analysis of biological samples in prospective controlled and real life studies.

- Salvatorelli E, Minotti G, Menna P. New targeted drugs for acute myeloid leukemia and antifungals: pharmacokinetic challenges and opportunities. Chemotherapy 2023. Online ahead of print

- Boriani G, Menna P, Morgagni R, Minotti G, Vitolo M. Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death. Chemotherapy 2023;68:61-72

- Charlier B, Coglianese A, Operto FF, Coppola GG, de Grazia U, Menna P, Filippelli A, Dal Piaz F, Izzo V. Development and validation of a UHPLC-MS/MS-based method to quantify cenobamate in human plasma samples . Molecules 2022;27:7325

- Cattaneo C, Marchesi F, Terrenato I, Bonuomo V, Fracchiolla NS, Delia M, Criscuolo M, Candoni A, Prezioso L, Facchinelli D, Pasciolla C, Del Principe MI, Dargenio M, Buquicchio C, Mitra ME, Farina F, Borlenghi E, Nadali G, Gagliardi VP, Fianchi L, Sciumè M, Menna P, Busca A, Rossi G and Pagano L. High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM study. J. Fungi 2022; 8:583

- Maschmeyer G, Bullinger L, Garcia-Vidal C, Herbrecht R, Maertens J, Menna P, Pagano L, Thiebaut-Bertrand A, Calandra T. Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society ( ICHS) and the European Leukemia Net (ELN). Leukemia, 2022, 36: 1450

- Minotti G, Salvatorelli E, Reggiardo G, Mangiacapra F, Camilli M, Menna P. Cardiac anthracycline accumulation and b-type natriuretic peptide to define risk and predictors of cancer treatment related early diastolic dysfunction. J Pharmacol Exp Ther. 2022; 381:266-273 .

- Minotti G, Reggiardo G, Camilli M, Salvatorelli E, Menna P. From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction. JACC: CARDIOONCOLOGY 2022; 1:139-140

- Menna P, Salvatorelli E, Del Principe MI, Perrone S, Pagano L, Marchesi F and Minotti G. Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life. Chemotherapy 2021; 66:47-52